Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | ABAT | P80404 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208895 | 1.00 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL19337855 | 1.00 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL14480001 | 1.00 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| SCHEMBL993866 | 1.00 | MMP2 (0.37) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL6079312 | 0.98 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL4093850 | 0.98 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL6081955 | 0.98 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Hydrochloric Acid SCHEMBL4426352 | 0.98 | MMP2 (0.36) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078882 | 0.93 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT | |
| Sulfuric Acid SCHEMBL6078890 | 0.93 | MMP2 (0.33) | MMP2ANPEPCHRNB2CHRNA4ABAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | claimed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079801-A | Synthesis method and analysis method of (1S, 4R) -4-amino-2-cyclopentene-1-carboxylic acid methyl ester tartrate | — | 2026-05-26 | — | — | CN | disclosed |
| CN-119431264-A | 3-Phenyl isoxazoline-5-formamide oxime ester compound and application thereof | 沈阳万菱生物技术有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| CN-112341350-A | Method for treating by-product after enzymatic resolution of gamma-lactam | 江苏威奇达药业有限公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-111072547-A | Chemical preparation method of 2-azabicyclo [2.2.1] hept-5-ene-3-ketone with optical activity | 南京正济医药研究有限公司 | 2020-04-28 | — | — | CN | disclosed |
| US-8906911-B2 | Chemokine receptor antagonists | ABBVIE INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2448916-B1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | REDDYS LAB LTD DR (IN) | 2014-09-03 | — | — | EP | disclosed |
| WO-2011003061-A2 | PRODUCTION OF TRAN S-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-01-06 | — | — | WO | disclosed |
| US-7038059-B2 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040121482-A1 | Process for preparation of 4-n-substituted amino-2-aza-1-oxabicyclo[3.3.0] oct-2-ene-6-carboxylic acid esters and process for preparation of their intermediates | KURARAY CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1334969-A1 | PROCESS FOR PREPARATION OF 4-N-SUBSTITUTED AMINO-2-AZA-1-OXABICYCLO 3.3.0]OCT-2-ENE-6-CARBOXYLIC ACID ESTERS AND PROCESS FOR PREPARATION OF THEIR INTERMEDIATES | KURARAY CO., LTD. (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6495711-B2 | 1-(TERT-BUTOXYCARBONYLAMINO)-4-METHOXYCARBONYL-CYCLOPENT-2-ENE STARTING BY REACTING 2-AZABICYCLO(2.2.1)HEPT-5-EN-3-ONE WITH AN ALCOHOL AND NONAQUEOUS ACID; CHEMICAL INTERMEDIATES TO ANTIVIRAL AGENTS AGAINST INFLUENZA VIRUS | BIOCRYST PHARMACEUTICALS INC. | 2002-12-17 | — | — | US | disclosed |
| EP-1206443-A2 | PROCESS FOR PREPARING (-)-(1S,4R) N-PROTECTED 4-AMINO-2-CYCLOPENTENE-1-CARBOXYLATE ESTERS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | BIOCRYST PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1165829-A1 | THE PREPARATION OF (trans)-4-AMINO-2-CYCLOPENTENE-1-CARBOXYLIC ACID DERIVATIVES | Chirotech Technology Limited (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001001569-A2 | PROCESS FOR PREPARING (-)-(1S,4R) N-PROTECTED 4-AMINO-2-CYCLOPENTENE-1-CARBOXYLATE ESTERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000058500-A1 | THE PREPARATION OF trans-4-AMINO-2-CYCLOPENTENE-1-CARBOXYLIC ACID DERIVATIVES | CHIROTECH TECHNOLOGY LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052524-A1 | Process for preparing (-)-(1S, 4R) N-protected 4-amino-2-cyclopentene-1-carboxylate esters | CPNE4, PYM1, CCNT1 | MMP2 4155/4885ANPEP 700/4885CHRNB2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.